These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 9675668)

  • 1. Retreatment with human leukocyte interferon alpha of chronic hepatitis C, recurring after a first cycle with recombinant interferon.
    Carrara M; Azzurro M; Adamo S
    Ital J Gastroenterol Hepatol; 1998 Apr; 30(2):234-5. PubMed ID: 9675668
    [No Abstract]   [Full Text] [Related]  

  • 2. [The retreatment with natural leukocyte interferon alfa-n3 of chronic hepatitis C patients: the intolerant and nonresponsive results to prior treatment with recombinant alfa interferon].
    Cagnoni C; Pancotti D; Carrara G
    Ann Ital Med Int; 1999; 14(3):159-65. PubMed ID: 10566181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of patients with HCV infection poorly tolerant to recombinant interferon alpha.
    Cagnoni C; Pancotti D; Carrara G
    Hepatogastroenterology; 2000; 47(31):199-203. PubMed ID: 10690609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of high dose of recombinant alpha 2b interferon on long term response in chronic hepatitis C and cirrhosis: prospective randomized multicentre study.
    Ascione A; De Luca M; Canestrini C; Di Costanzo GG; Raimondo G; Longo G; Manns MP; Tillmann HL; Forte GB; Rocco P; Biceglia O; Faleo D; Vinelli F; Cela EM; Amitrano L; Addario L; Gigliotti T
    Ital J Gastroenterol Hepatol; 1998 Oct; 30(5):517-23. PubMed ID: 9836109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon retreatment of patients with chronic hepatitis C. A long-term follow-up.
    Spadaro A; Freni MA; Ajello A; Alessi N; Barbaro E; Resta ML; Ferraü O
    Hepatogastroenterology; 1999; 46(30):3229-33. PubMed ID: 10626191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute onset of nephrotic syndrome during interferon-alpha retreatment for chronic active hepatitis C.
    Nishimura S; Miura H; Yamada H; Shinoda T; Kitamura S; Miura Y
    J Gastroenterol; 2002; 37(10):854-8. PubMed ID: 12424571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retreatment of non-responder or relapser chronic hepatitis C patients with interferon plus ribavirin vs interferon alone.
    Milella M; Santantonio T; Pietromatera G; Maselli R; Casalino C; Mariano N; Genchi C; Pastore G
    Ital J Gastroenterol Hepatol; 1999 Apr; 31(3):211-5. PubMed ID: 10379482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
    J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
    Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
    Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term interferon therapy for chronic hepatitis C patients with low viral load.
    Sato Y; Tokuue H; Kawamura N; Nezu-Yajima S; Nakajima H; Ishida H; Takahashi S
    Hepatogastroenterology; 2004; 51(58):968-72. PubMed ID: 15239226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C.
    Fernández I; Castellano G; de Salamanca RE; Colina F; Gómez de la Cámara A; Morán MJ; Muñoz R; Solís-Herruzo JA
    Scand J Gastroenterol; 2003 Mar; 38(3):314-9. PubMed ID: 12737448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can science meet the challenges of the HCV pandemic: new treatment options for chronic hepatitis C.
    Roehr B
    J Int Assoc Physicians AIDS Care; 1998 Jul; 4(7):24-9. PubMed ID: 11365638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C.
    Wirth S; Lang T; Gehring S; Gerner P
    Hepatology; 2002 Nov; 36(5):1280-4. PubMed ID: 12395341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon alfacon-1: new preparation. Basically a me-too interferon alfa.
    Prescrire Int; 2003 Jun; 12(65):95-6. PubMed ID: 12825573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
    Mamori S; Suzuki F; Hosaka T; Akuta N; Someya T; Kobayashi M; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study of the relapse of patients with chronic hepatitis B undergoing first and repeated recombinant interferon-alpha therapy during long-term follow up].
    Liu DL; Luo KX; Feng XR; Fu QX; Hou JL
    Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(26):1840-3. PubMed ID: 17922996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
    Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
    Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful application of highly purified natural interferon alpha (multiferon) in a chronic hepatitis C patient resistant to preceding treatment approaches.
    Musch E; Malek M; von Eick H; Chrissafidou A
    Hepatogastroenterology; 2004; 51(59):1476-9. PubMed ID: 15362781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study.
    Bargiggia S; Thorburn D; Anderloni A; Ardizzone S; Giorgi A; Bianchi Porro G; Parente F
    Aliment Pharmacol Ther; 2005 Aug; 22(3):209-15. PubMed ID: 16091058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Human recombinant alfa-2 interferon in the treatment of hairy cell leukemia].
    Wolska-Smoleń T; Skotnicki AB; Blicharski J; Zduńczyk A; Sasiadek U; Pituch-Noworolska A; Bielawiec M; Hansz J; Hellmann A; Hołowiecki J
    Acta Haematol Pol; 1988; 19(3-4):113-25. PubMed ID: 3252660
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.